HHS’ pandemic response shop, elevated last year to report directly to the HHS secretary, would use the $10.5 billion the White House requests for the office in fiscal 2024 to bolster the domestic supply chain for medications and other medical products. The White House this month announced a plan to produce at least 25% of all active pharmaceutical ingredients for small molecule drugs in the United States in five years. Those goals align with that of a new bipartisan congressional...